Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Conditions
Keywords
Natural killer/T-cell lymphoma, Sintilimab, Pegaspargase, Anlotinib
Brief summary
The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with Pegaspargase and anlotinib in the treatment of stage IV NK/T-cell lymphoma patients unfit for high-dose chemotherapy.
Detailed description
Stage IV NK/T-cell lymphoma has a poor prognosis, and autologous hematopoietic stem cell transplantation can improve the prognosis of patients who have achieved remission after chemotherapy. The median survival time for patients who were not suitable for transplantation was about 1 year. Asparaginase is the backbone drug for the treatment of NK/T-cell lymphoma. PD-1 antibody is effective for relapsed/refractory NK/T-cell lymphoma. Our previous study found that anlotinib is active in relapsed/refractory NK/T Cell lymphoma. This study is aimed to investigate the efficacy and safety of Sintilimab, a PD-1 antibody approved in China, in combination with Pegaspargase and anlotinib in the treatment of stage IV NK/T-cell lymphoma patients unfit for high-dose chemotherapy.
Interventions
DRUGLEAP regimen
Patients will be given LEAP regimen every 3 weeks for 8 cycles.
Sponsors
Rong Tao
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histopathology and immunohistochemistry confirmed diagnosis of NK/T-cell lymphoma according to WHO 2016 criteria. * Stage IV disease according Lugano 2014 staging system. Newly diagnosed patients, or relapsed disease without a history of asparaginase-containing regimen. * PET/CT or CT/MRI with at least one objectively evaluable lesion. * The age is greater than 65 years old. Those who are younger than 65 years should have a documented history unfit for high-dose combination chemotherapy (ie. high doses of methotrexate or high doses of dexamethasone, or autologous hematopoietic stem cell transplantation). * General status ECOG score 0-3 points. * The laboratory test within 1 week before enrollment meets the following conditions: Blood routine: Hb\>80g/L, PLT\>50×109/L. Liver function: ALT, AST, TBIL ≤ 2 times the upper limit of normal. Renal function: Cr is normal. Coagulation : plasma fibrinogen ≥ 1.0g / L. Cardiac function: LVEF≥50%, ECG does not suggest any acute myocardial infarction, arrhythmia or atrioventricular conduction above I Blocking. * Sign the informed consent form. * Voluntary compliance with research protocols, follow-up plans, laboratory and auxiliary examinations.
Exclusion criteria
* Patients with a history of pancreatitis. * Active infection requires ICU treatment. * Concomitant HCV or HIV infection. Patients who are infected with HBV at the same time are not excluded. * Serious complications such as fulminant DIC. * Significant organ dysfunction: such as respiratory failure, NYHA classification ≥ 2 chronic congestive heart failure, decompensation Hepatic or renal insufficiency, high blood pressure and diabetes that cannot be controlled despite active treatment, and cerebral vascular thrombosis or hemorrhagic time within the past 6 months. * Pregnant and lactating women. * Had a history of autoimmune diseases, and disease was active in the last 6 months, and was still taking oral immunosuppression in the past three months. For the treatment, the daily dose of oral prednisone is greater than 10 mg. * Those who were known to be allergic to drugs in the study regimen. * Patients with other tumors who require surgery or chemotherapy within 6 months. * Other experimental drugs are being used.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete response rate | Week 24 +/-7 days | The complete response rate will be assessed on week 24. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | 1-year | Progression free survival is the time from entry onto the treatment until lymphoma progression or death of any reason. |
| Overall response rate | Week 24 +/-7 days | The overall response rate will be assessed on Week 24 |
| Treatment-Related Adverse Events as Assessed by CTCAE v4.0 | Day 1 of each course of chemotherapy and then every 3 months for 1 year | Treatment-Related Adverse Events will be assessed and graded by NCI CTCAE v4.0. |
| Overall survival | 1-year | Overall survival is defiend as the time from entry onto the treatment until death of any reason |
Countries
China
Contacts
Primary ContactRong Tao, MD., PhD
Backup ContactWen-Hao Zhang, MD., PhD
Outcome results
None listed